The human population is currently faced with the potential use of natural or recombinant
variola and monkeypox viruses as biological weapons. Furthermore, the emergence of …

Background The emergence of human monkeypox and the potential use of recombinant
variola and monkey-pox viruses as biological terrorist agents have necessitated the …

The intranasal lethal mousepox model employing the A/Ncr mouse strain is used to evaluate
anti-orthopoxvirus therapies. These infections mimic large droplet transmission and result in …

Monkeypox virus (MPXV) is an orthopoxvirus closely related to variola, the etiological agent
of smallpox. In humans, MPXV causes a disease similar to smallpox and is considered to be …

Smallpox, caused by Variola virus (VARV), was eradicated in 1980; however, VARV
bioterrorist threats still exist, necessitating readily available therapeutics. Current …

Concerns over the potential use of variola virus as a biological weapon have prompted new
interest in the development of small molecule therapeutics to prevent and treat smallpox …

Orthopoxvirus infections, such as smallpox, can lead to severe systemic disease and result
in considerable morbidity and mortality in immunologically naïve individuals. Treatment …

In 2007, the United States–Food and Drug Administration (FDA) issued guidance
concerning animal models for testing the efficacy of medical countermeasures against …

Monkeypox virus (MPXV) infections in humans have historically been restricted to regions of
endemicity in Africa. However, in 2022, an alarming number of MPXV cases were reported …

The threat of smallpox release and use as a bioweapon has encouraged the search for new
vaccines and antiviral drugs, as well as development of new small-animal models in which …